A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care ...
Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...
For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Rate of medical ...
For some endocrine conditions, surgery is the best treatment option and can relieve symptoms. An endocrine surgeon will explain your options and help you decide if surgery is right for you. You’ll ...
Endocrine therapy remains a backbone of adjuvant therapy for women with hormone receptor–positive early-stage breast cancer. Numerous studies have demonstrated the benefit of ovarian function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results